Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2020-12-31 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司2020年度持续督导工作现场检查结果及提请公司注意事项
Audit Report / Information Classification · 90% confidence The document is a report from a sponsoring institution (中信证券股份有限公司) regarding the 2020 annual continuous supervision on a listed company (厦门艾德生物医药科技股份有限公司). It mentions a '现场检查报告' (on-site inspection report) related to governance, internal controls, disclosure, and compliance with stock exchange rules. The document is relatively short (597 characters) and includes an attachment titled '定期现场检查报告'. This suggests it is a regulatory or supervisory report rather than a full annual report or audit report. It is not an announcement of voting results, management changes, or earnings. The content aligns best with an Audit Report / Information (AR) category, as it involves an audit-like supervisory inspection and compliance check. The document is not merely an announcement of a report but contains substantive supervisory findings. Therefore, the classification is AR with high confidence. FY 2020
2020-12-31 Chinese
中信证券股份有限公司关于公司2020年持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年持续督导现场检查报告" which translates to "2020 Continuous Supervision On-site Inspection Report". It is issued by a sponsoring institution (中信证券股份有限公司) regarding a company (厦门艾德生物医药科技股份有限公司). The content includes detailed inspection items such as company governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, shareholder commitments, and other important matters. The document is a detailed report of an on-site inspection related to regulatory supervision and compliance for the year 2020. It is not an annual report, earnings release, or a simple announcement. It is a standalone audit or inspection report focusing on compliance and internal controls, which fits the category of Audit Report / Information (AR). The document length is 4032 characters, which is sufficient to contain substantive content rather than a mere announcement. Therefore, the classification is AR with high confidence. FY 2020
2020-12-31 Chinese
中信证券股份有限公司关于公司2020年持续督导培训情况的报告
Audit Report / Information Classification · 90% confidence The document is titled as a report from CITIC Securities Co., Ltd. regarding the 2020 continuous supervision training for Xiamen Aide Biomedical Technology Co., Ltd. It references regulatory guidelines from the Shenzhen Stock Exchange and details a training session conducted for company directors, supervisors, and senior management on topics such as information disclosure, corporate governance, insider trading prevention, and related party transactions. The document is a formal report on the training activity rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or audit information. The content aligns with a report on ongoing supervision and training activities required by regulatory bodies, which fits best under Audit Report / Information (AR) as it relates to regulatory compliance and internal control training rather than a full annual report or other categories. FY 2020
2020-12-31 Chinese
关于特定股东股份减持计划完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a specific shareholder's share reduction plan. It details the shareholder's name, the number of shares reduced, the reduction period, and confirms compliance with relevant securities laws and regulations. There is no financial report or detailed financial data presented, but rather a disclosure about a transaction involving the company's shares by a shareholder. This fits the category of a Transaction in Own Shares (POS), which covers company share buybacks or sales by shareholders.
2020-12-31 Chinese
关于与广生堂达成靶向药物临床研究合作的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a cooperation agreement between the company and another pharmaceutical company for clinical research collaboration. It details the nature of the cooperation, the parties involved, and the expected impact on the company. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is relatively short (2336 characters) and serves as a formal disclosure of a business cooperation agreement rather than a financial report or regulatory filing about financial performance. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a business cooperation announcement, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2020-12-25 Chinese
关于特定股东股份减持计划完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a specific shareholder's share reduction plan. It details the shareholder's name, the number of shares reduced, the period of reduction, and confirms compliance with relevant securities laws and regulations. There is no financial report, earnings data, or management discussion. The content focuses on a shareholder's transaction in their own shares, specifically a reduction (sale) of shares. This fits the definition of 'Transaction in Own Shares' (POS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2020-12-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.